Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07152769
Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC (ITUS)
Iparomlimab and Tuvonralimab Combined With Gemcitabine and Cisplatin (GC) Versus Sintilimab Combined With GC as First-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma: A Single-Center, Open-Label, Randomized Controlled Phase II Study
Sponsor: Fudan University
Conditions
Advanced Intrahepatic Cholangiocarcinoma
Interventions
Iparomlimab and Tuvonralimab + GC Sintilimab + GC
Updated 1 time since 2025 Last updated: Aug 26, 2025 Started: Oct 15, 2025 Primary completion: Feb 29, 2028 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Advanced Intrahepatic Cholangiocarcinoma, this trial is actively recruiting participants. The trial is conducted by Fudan University and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Fudan University
Data source: Fudan University
For direct contact, visit the study record on ClinicalTrials.gov .